Retrospective cohort study investigates tafamidis effects on hospital costs and readmissions for heart failure in ATTR-CM patients, suggesting significant healthcare savings.
Key Points
This study aims to evaluate the individual effects of tafamidis on hospitalizations and costs in patients with transthyretin amyloid cardiomyopathy.
Retrospective cohort study at a tertiary care center
116 patients with ATTR-CM initiated on tafamidis therapy
Each patient served as their control
Hospitalization data was analyzed for one year pre- and post-treatment
Generalised linear models used to compare hospitalization metrics
Significant reduction in hospital days from 2.66 to 1.55 days per year (p < 0.001)
43% reduction in heart failure readmissions within one year
Cost savings of approximately $3285 per patient due to reduced length of stay
Greater benefits seen in patients with NYHA class I-II and preserved LVEF